S1 Ep225: How Will Orca-T Impact the Hematologic Oncology Paradigm?
About this episode
The episode discusses the impact of the FDA approval of Orca-T on hematologic oncology treatments and patient outcomes.
Following the FDA approval of allogeneic regulatory T cell–containing immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi; Orca-T), CancerNetwork® spoke with Wendy Stock, MD, about what this decision means for the treatment of patients undergoing hematopoietic stem cell transplantation for different hematologic malignancies. Additionally, she discussed how this option fits into the treatment landscape alongside other options like posttransplant cyclophosphamide (PTCy) and other next steps for improving outcomes associated with matched donor transplants. Stock reviewed findings from the phase 3 Precision-T trial (NCT05316701) that supported the approval of Orca-T, noting that the data appeared to be “effective across all populations” for patients with acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome (MDS), and mixed-phenotype acute leukemia. Furthermore, she detailed what adoption of Orca-T might look like on an operational level, described the agent’s ability to reduce the risk of graft-versus-host disease, and emphasized referring patients early to transplantation. The approval, Stock said, marks the…
More episodes of Oncology On The Go
- S1 Ep224: Managing Insomnia in Cancer Care: Sleep Hygiene, CBT-I, and Medications
- S1 Ep222: How Does a Death Doula Support Patients With Cancer?
- S1 Ep223: Optimizing Frontline Selection and Treatment-Free Remission in CML
- S1 Ep221: Redefining Lymphoma Standards of Care: Top Datasets From ASCO and EHA 2026
- S1 Ep220: Exploring The Future of Artificial Intelligence and Thoracic Oncology
- S1 Ep219: Navigating Personality Disorders in Cancer Care
Explore listener stats, chart rankings, contacts and more on the Oncology On The Go podcast page.